WHO's 45% dementia-risk figure raises UAE screening pressure

WHO's 45% dementia-risk figure gives UAE providers a direct reason to add cognitive-risk checks to diabetes, hypertension, lipid and home-care workflows.

The practical audience is healthcare executives, COOs, medical directors and CFOs. The issue is where screening sits, who documents it, and whether payers treat prevention as chronic-disease management or as a wellness add-on.

What WHO changed in 2026

The WHO announcement, released on 15 July 2026, updates its 2019 guidance on cognitive decline and dementia risk reduction. WHO said more than 57 million people live with dementia worldwide, nearly 10 million people are newly diagnosed each year, and Alzheimer disease accounts for an estimated 60-70% of cases.

"We know more today than ever before about what drives dementia risk," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

WHO places dementia prevention inside existing noncommunicable disease operations. The named risk factors include tobacco use, alcohol use, physical inactivity, social isolation, air pollution, hypertension, diabetes and high cholesterol. WHO also says hearing aids may be offered for risk reduction when clinically appropriate.

• Recommended: physical activity, tobacco cessation, lower alcohol consumption, healthy diet, cognitive training and social activity.
• New in scope: lower exposure to air pollution as part of dementia-risk prevention.
• Clinical link: hypertension, diabetes and high cholesterol control tied to brain-health protection.
• Excluded without deficiency: vitamin B, vitamin E, omega-3 and multivitamin supplementation.

Why this matters for UAE operators

For UAE providers, the operating question is whether cognitive-risk assessment becomes part of standard NCD follow-up. Ministry of Health and Prevention (MOHAP), Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DOH) oversee the care settings most likely to absorb the work: primary care, geriatrics, chronic-disease clinics and home care.

MOHAP has already linked NCD surveillance to national health information systems. In a 2026 workshop with WHO, MOHAP said national indicators include physical inactivity, unhealthy diets, tobacco use, overweight, obesity, diabetes and hypertension across healthcare levels. Those categories now sit inside WHO's dementia-prevention guidance.

DHA has also moved more care for older residents into the home. On 29 April 2025, DHA launched the Enaya home-care initiative for senior citizens, with medical examinations and services aimed at 155,000 people enrolled in Dubai's Unified Government Health Insurance Programme. That model gives Dubai operators a clear site for cognitive screening, caregiver education and referral protocols.

The execution gap

A 2026 environmental scan in BMC Health Services Research found fragmented dementia-specific services in the UAE, limited workforce preparation and heavy reliance on families and private care providers. The study reviewed 61 grey-literature sources and reported fieldwork across 2023-2025, including interviews with healthcare professionals involved in dementia care.

The same study found no national dementia strategy in the UAE. It also reported delayed diagnosis, limited respite care and inconsistent dementia-specific training. For private hospitals, clinics and home-care firms, that means service gaps may arrive before national reimbursement rules are clear.

The cost signal is large. WHO estimates dementia costs the global economy US$ 1.3 trillion a year, with about half of that cost driven by unpaid care from families and friends. In the UAE, that burden intersects with paid domestic help and private home-care agencies, making dementia prevention a staffing, training and package-design issue.

Providers should watch for DHA, DOH and MOHAP circulars that convert WHO's 2026 recommendations into licensing standards, screening expectations or quality measures. The near-term move is concrete: add cognitive-risk prompts to diabetes, hypertension, lipid and hearing-loss workflows, then train nurses and physicians to document referrals in the same way across sites.

The commercial test is reimbursement. If payers treat cognitive-risk screening as chronic-disease management, providers can build scaled pathways. If payers exclude it, dementia prevention will sit inside wellness packages, employer health checks and premium home-care plans.